<img height="1" width="1" src="https://www.facebook.com/tr?id=200201724533423&amp;ev=PageView &amp;noscript=1">
Contact Us

    GENOMIND PRESS ROOM

    March 25, 2020

    Helping You Shift to Telepsychiatry in the Era of COVID-19

    Recent government actions enable telepsychiatry

    Continue Reading...
    March 19, 2020

    Genomind Launches Express Ship-to-Patient Capability for Genomind Professional PGx Express Test Enabling Access to Critical Mental Health Treatment Information

    As the first company to offer direct-to-patient, at-home mental health pharmacogenetic testing, Genomind is helping patients and physicians gain actionable mental health insights without having to leave their homes

    Continue Reading...
    March 10, 2020

    Genomind Substantially Increases Customer Access to Pharmacogenetic Mental Health Testing Through Expanded Partnership With Jewel-Osco

    Latest agreement quadruples number of pharmacies in Albertsons Companies offering Genomind’s tests and services

    Continue Reading...
    December 16, 2019

    Genomind Expands Collaboration to Provide Access to Genetics-Based Mental Health Test to Customers in All Pennsylvania ACME Markets

    Specially trained ACME pharmacists will identify and work with patients who may benefit from Genomind Professional PGx Express – the most comprehensive genetic testing service aimed at improving mental health treatments

    Continue Reading...
    September 16, 2019

    Researchers Present New Data on the Utility of Genomind's Mental Health Pharmacogenomic Testing at Upcoming Scientific Conferences

    Abstracts presented at this year’s Psych Congress and NEI Congress expand the increasing body of evidence supporting Genomind’s approach to integrating pharmacogenomics into mental health treatment

    Continue Reading...
    August 5, 2019

    Genomind Expands Mental Health Genetic Testing Services with New Genomind Professional PGx Express

    Product expansion comes as UnitedHealthcare issues positive coverage decision on PGx testing, including Genomind’s service, for certain patients with major depressive disorder or anxiety

    Continue Reading...

    SEARCH NEWS